Targeting heat shock response pathways to treat pancreatic cancer

Drug Discovery Today

Volumn 17, Issue 1-2, 2012, Pages 35-43

  Xia, Yi ^a   Rocchi, Palma ^b   Iovanna, Juan L ^b   Peng, Ling ^a  

^a AIX MARSEILLE UNIVERSITÉ   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTINEOPLASTIC AGENT; CANCER VACCINE; CELASTROL; GANETESPIB; GELDANAMYCIN; GEMCITABINE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; KNK 437; LEVO EPIGALLOCATECHIN 3 GALLATE; LY 101 4B; OXYTHIAMINE; QUERCETIN; RETASPIMYCIN; SMALL INTERFERING RNA; TANESPIMYCIN; TRIPTOLIDE; UNCLASSIFIED DRUG; WITHAFERIN A; WJQ 101;

CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER THERAPY; DRUG STRUCTURE; HEAT SHOCK RESPONSE; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PANCREAS CANCER; REVIEW;

ANIMALS; DRUG DELIVERY SYSTEMS; HEAT-SHOCK RESPONSE; HUMANS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84855847704     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.09.016     Document Type: Review

References (69)

1. A. Stathis, and M.J. Moore Advanced pancreatic carcinoma: current treatment and future challenges Nat. Rev. Clin. Oncol. 7 2010 163 172
2. E. Mini Cellular pharmacology of gemcitabine Ann. Oncol. 17 Suppl. 5 2006 V7 V12
3. F. Rivera Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy Cancer Treat. Rev. 35 2009 335 339
4. H.H. Wong, and N.R. Lemoine Pancreatic cancer: molecular pathogenesis and new therapeutic targets Nat. Rev. Gastroenterol. Hepatol. 6 2009 412 422
5. S.E. Kern The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting J. Pathol. 223 2011 295 306
6. A.S. Strimpakos The molecular targets for the diagnosis and treatment of pancreatic cancer Gut Liver 4 2010 433 449
7. M.J. Moore Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol. 25 2007 1960 1966 (Pubitemid 46972777)
8. J. Long Overcoming drug resistance in pancreatic cancer Expert Opin. Ther. Targets 15 2011 817 828
9. R.I. Morimoto, and M.G. Santoro Stress-inducible responses and heat shock proteins: new pharmacologic targets for cytoprotection Nat. Biotechnol. 16 1998 833 838 (Pubitemid 28405852)
10. M. Sherman, and G. Multhoff Heat shock proteins in cancer Ann. N. Y. Acad. Sci. 1113 2007 192 201 (Pubitemid 350015025)
11. G. Jego Targeting heat shock proteins in cancer Cancer Lett. 2011 10.1016/j.canlet.2010.1010.1014
12. A.A. Khalil Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets? Biochim. Biophys. Acta 1816 2011 89 104
13. I. Shamovsky, and E. Nudler New insights into the mechanism of heat shock response activation Cell. Mol. Life Sci. 65 2008 855 861
14. M. kerfelt Heat shock factors: integrators of cell stress, development and lifespan Nat. Rev. Mol. Cell Biol. 11 2010 545 555
15. L. Whitesell, and S. Lindquist Inhibiting the transcription factor HSF1 as an anticancer strategy Expert Opin. Ther. Targets 13 2009 469 478
16. M. kerfelt Heat shock factors at a crossroad between stress and development Ann. N. Y. Acad. Sci. 1113 2007 15 27
17. D. Lanneau Heat shock proteins: essential proteins for apoptosis regulation J. Cell. Mol. Med. 12 2008 743 761 (Pubitemid 351718062)
18. T.M. Gress Differential expression of heat shock proteins in pancreatic carcinoma Cancer Res. 54 1994 547 551 (Pubitemid 24053199)
19. L. Whitesell, and S.L. Lindquist HSP90 and the chaperoning of cancer Nat. Rev. Cancer 5 2005 761 772 (Pubitemid 41400776)
20. M.V. Powers, and P. Workman Inhibitors of the heat shock response: biology and pharmacology FEBS Lett. 581 2007 3758 3769 (Pubitemid 47081010)
21. C.G. Concannon On the role of Hsp27 in regulating apoptosis Apoptosis 8 2003 61 70 (Pubitemid 36133139)
22. A.P. Arrigo Hsp27 (HspB1) and [alpha]B-crystallin (HspB5) as therapeutic targets FEBS Lett. 581 2007 3665 3674
23. P. Rocchi Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer Cancer Res. 64 2004 6595 6602 (Pubitemid 39297919)
24. P. Rocchi Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis Cancer Res. 65 2005 11083 11093 (Pubitemid 41713379)
25. P. Rocchi Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro BJU Int. 98 2006 1082 1089 (Pubitemid 44536463)
26. V. Baylot OGX-427 Inhibits Tumor Progression and Enhances Gemzar Chemotherapy in Pancreatic Cancer Cell Death Dis. 2011 in press
27. M. Kamada Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells Mol. Cancer Ther. 6 2007 299 308 (Pubitemid 46206694)
28. H.W. Hirte Phase I trial of OGX-427, a 2′methoxyethyl antisense oligonucleotide (ASO), against Hsp27: final results J. Clin. Oncol. 28 2010 15s (Suppl.; abstr 3077)
29. S. Mori-Iwamoto Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine Int. J. Oncol. 31 2007 1345 1350
30. C. Melle Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker Clin. Chem. 53 2007 629 635 (Pubitemid 46580232)
31. S. Mori-Iwamoto Interferon-gamma down-regulates heat shock protein 27 of pancreatic cancer cells and helps in the cytotoxic effect of gemcitabine Pancreas 38 2009 224 226
32. Y. Xia Novel triazole ribonucleoside down-regulates heat shock protein 27 and induces potent anticancer activity on drug-resistant pancreatic cancer J. Med. Chem. 52 2009 6083 6096
33. Peng, L. et al.(2009) Novel triazole nucleoside derivatives, their preparation and their application in therapeutics. PCT/EP2009/055213. WO/2009/133147
34. S. Yokota Benzylidene lactam compound, KNK437, a novel inhibitor of acquisition of thermotolerance and heat shock protein induction in human colon carcinoma cells Cancer Res. 60 2000 2942 2948 (Pubitemid 30395819)
35. K. Taba KNK437 downregulates heat shock protein 27 of pancreatic cancer cells and enhances the cytotoxic effect of gemcitabine Chemotherapy 57 2010 12 16
36. K. Taba Heat-shock protein 27 is phosphorylated in gemcitabine-resistant pancreatic cancer cells Anticancer Res. 30 2010 2539 2543
37. H. Zhang Inhibition of protein phosphorylation in MIA pancreatic cancer cells: confluence of metabolic and signaling pathways J. Proteome Res. 9 2010 980 989
38. S. Kostenko, and U. Moens Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology Cell. Mol. Life Sci. 66 2009 3289 3307
39. C.G. Evans Heat shock protein 70 (hsp70) as an emerging drug target J. Med. Chem. 53 2010 4585 4602
40. M.P. Mayer, and B. Bukau Hsp70 chaperones: cellular functions and molecular mechanism Cell. Mol. Life Sci. 62 2005 670 684
41. A. Aghdassi Heat shock protein 70 increases tumorigenicity and inhibits apoptosis in pancreatic adenocarcinoma Cancer Res. 67 2007 616 625 (Pubitemid 46192200)
42. R.E. Wang Inhibition of heat shock induction of heat shock protein 70 and enhancement of heat shock protein 27 phosphorylation by quercetin derivatives J. Med. Chem. 52 2009 1912 1921
43. P.A. Phillips Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70 Cancer Res. 67 2007 9407 9416 (Pubitemid 47535931)
44. R. Boly Quercetin inhibits a large panel of kinases implicated in cancer cell biology Int. J. Oncol. 38 2011 833 842
45. V. Dudeja Heat shock protein 70 inhibits apoptosis in cancer cells through simultaneous and independent mechanisms Gastroenterology 136 2009 1772 1782
46. V. Dudeja The role of heat shock proteins in gastrointestinal diseases Gut 58 2009 1000 1009
47. S.D. Westerheide Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death J. Biol. Chem. 281 2006 9616 9622 (Pubitemid 43864680)
48. D.V. Titov XPB, a subunit of TFIIH, is a target of the natural product triptolide Nat. Chem. Biol. 7 2011 182 188
49. A. Subbarao Sreedhar Hsp90 isoforms: functions, expression and clinical importance FEBS Lett. 562 2004 11 15
50. U. Banerji Heat shock protein 90 as a drug target: some like it hot Clin. Cancer Res. 15 2009 9 14
51. C. Moser Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer Anticancer Res. 29 2009 2031 2042
52. M.A. Biamonte Heat shock protein 90: inhibitors in clinical trials J. Med. Chem. 53 2010 3 17
53. Y.S. Kim Update on Hsp90 inhibitors in clinical trial Curr. Top. Med. Chem. 9 2009 1479 1492
54. J.R. Porter Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy Curr. Opin. Chem. Biol. 14 2010 412 420
55. S.A. Lang Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth Clin. Cancer Res. 13 2007 6459 6468 (Pubitemid 350075036)
56. D. Song Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer Mol. Cancer Ther. 7 2008 3275 3284
57. Y. Wang STA-9090 a small-molecule Hsp90 inhibitor for the potential treatment of cancer Curr. Opin. Investig. Drugs 11 2010 1466 1476
58. T. Zhang A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells Mol. Cancer Ther. 7 2008 162 170
59. Y. Yu Withaferin A targets heat shock protein 90 in pancreatic cancer cells Biochem. Pharmacol. 79 2010 542 551
60. Y. Li (-)-Epigallocatechin-3-gallate inhibits Hsp90 function by impairing Hsp90 association with cochaperones in pancreatic cancer cell line Mia Paca-2 Mol. Pharm. 6 2009 1152 1159
61. B.H. Segal Heat shock proteins as vaccine adjuvants in infections and cancer Drug Discov. Today 11 2006 534 540 (Pubitemid 43732542)
62. M.H. Manjili Cancer immunotherapy and heat-shock proteins: promises and challenges Expert Opin. Biol. Ther. 4 2004 363 373 (Pubitemid 38352131)
63. Z. Li Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia Clin. Cancer Res. 11 2005 4460 4468 (Pubitemid 40825636)
64. R.J. Amato Heat-shock protein-peptide complex-96 for the treatment of cancer Expert Opin. Biol. Ther. 7 2007 1267 1273 (Pubitemid 47307265)
65. L. Pirkkala Roles of the heat shock transcription factors in regulation of the heat shock response and beyond FASEB J. 15 2001 1118 1131 (Pubitemid 32436297)
66. E. de Billy Drugging the heat shock factor 1 pathway: exploitation of the critical cancer cell dependence on the guardian of the proteome Cell Cycle 8 2009 3806 3808
67. A. Rossi Targeting the heat shock factor 1 by RNA interference: a potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer Cancer Res. 66 2006 7678 7685 (Pubitemid 44289226)
68. V. Dudeja Prosurvival role of heat shock factor 1 in the pathogenesis of pancreatobiliary tumors Am. J. Physiol. Gastrointest. Liver Physiol. 300 2011 G948 G955
69. Y. Xia Targeting Heat Shock Factor 1 with A Triazole Nucleoside Analog Elicits Potent Anticancer Activity on Drug-resistant Pancreatic Cancer Cancer Lett. 2011 in press